Articles tagged with Vaccine Research
Researchers analyzed over 4 million Twitter posts to find that fact-related users were negatively associated with vaccination rates, while fake-news users showed no significant impact. Exclusive fact-based users were more likely to be verified accounts with higher online influence.
A new study by University of Southampton researchers found that a third COVID-19 vaccination improves immune responses in blood cancer patients. The study showed that 92% of patients without recent anti-CD20 treatment had improved antibody responses after the third dose.
Researchers synthesized 46 reports on mass vaccination clinics to offer guidance on planning, logistics, and human resources. Key findings highlight the importance of strong recommendations from healthcare providers in improving vaccine uptake and confidence.
A large-scale registry study found no association between COVID-19 vaccination during pregnancy and increased risk of preterm birth, growth retardation, or neonatal care. Vaccination was associated with a slightly lower risk of neonatal care and provided protection against COVID-19 for the newborn.
Researchers found that people who had COVID-19 and then got vaccinated generated an immune response more specific to fighting viral infections, producing a broader antibody response. This hybrid immunity also produced a cellular immune response called Th1 response, which is antiviral.
A recent study published in Vaccine found that nearly 90% of healthcare workers accepted COVID-19 vaccines, particularly those serving immigrant communities. The researchers highlight the importance of education and interpersonal communication in influencing vaccine decisions.
A new model suggests that antibodies select antigens based on their surface characteristics, similar to a child playing on stepping stones. The researchers used DNA origami to simulate the behavior of antibodies and found that they tend to favor closer antigen distances.
A Mayo Clinic study of 106,349 primary care patients found that hospitalization rates for breakthrough COVID-19 were extremely low, even among those previously infected or vaccinated. The study supports previous findings that vaccination is the best way to prevent severe COVID-19 infection and hospitalization.
A booster dose of the Pfizer/BioNTech vaccine significantly increases antibodies against SARS-CoV-2, reversing a drop in immunity after two doses. In subjects given CoronaVac or Oxford-AstraZeneca vaccines, the booster raised immunity by a factor of 25 and 7, respectively.
Research in the Journal of Hepatology suggests that COVID-19 vaccines are unlikely to cause liver injury, but liver transplant patients may experience delayed care due to the pandemic. The study found that vaccinated patients with liver disease had a lower antibody response compared to healthy patients.
A new study published in Frontiers in Oncology has shown that mRNA-based Covid-19 vaccines are well-tolerated by high-risk patients with impaired immunity. The trial enrolled 566 patients and found no evidence of increased adverse events or interference with treatment, reassuring vaccine-hesitant immunocompromised individuals.
A study found that double vaccinated individuals generate a potent and broad neutralizing antibody response after a delta breakthrough infection. This response provides protection against current variants of concern, including omicron.
HPV vaccine approval led to increased screening and vaccination rates, resulting in a decrease in HPV-associated cancer cases. The study found significant declines in cervical, anal, and oropharyngeal cancers during this period.
A recent survey of over 3,200 NHS healthcare workers found that most preferred education and support as a solution to boost vaccination uptake. The study suggests that mandatory vaccinations may actually worsen trust and lead to thousands of staff leaving the profession.
Researchers at West Virginia University are using machine learning and geographic information systems to identify areas with low COVID-vaccine uptake. They aim to pinpoint counties with increased risk of outbreaks, predict where testing is most crucial, and develop targeted interventions to increase testing rates. By acknowledging comm...
Researchers found that some painkillers and fever medications may help fight infection, while others can weaken the immune system. The review highlights the need for more studies on the impact of these medicines on infectious diseases.
Researchers found that two-dose mRNA vaccines against the original and early variants of the SARS-CoV-2 virus offer little to no protection against the omicron variant. A third COVID-19 mRNA vaccine booster shot, however, enhances immune response and provides comparable protection to the delta variant.
Research reveals SARS-CoV-2 can have multiple variants in one person, with some hiding in specific cells like kidneys or spleens. This can make complete virus clearance more difficult, as the body struggles to defend against dominant strains.
A Brazilian study of 2,777 patients hospitalized between January 5 and September 12, 2021 found that vaccination was the sole predictor of mortality in those over 60 with kidney failure. Vaccination also reduced hospitalization risk among non-vaccinated patients with comorbidities.
A University of Ottawa group is conducting research to equip healthcare professionals with resources to aid patients in French-speaking minority settings make informed decisions about COVID-19 vaccines. The project aims to address language barriers and combat patient disinformation.
An analysis of pre-Omicron data found that COVID-19 vaccines retain nearly all their ability to prevent severe disease up to six months after full vaccination. Protection against severe COVID-19 dropped by an average of 10 percentage points over the same interval.
A Kaiser Permanente study published in Nature Medicine found that three doses of the Moderna COVID-19 vaccine were highly effective against hospitalization caused by infection from either the omicron or delta variant. The research suggests that third doses may be needed sooner than previously thought to protect against omicron infectio...
A University of Minnesota-led study found that COVID-19 boosters significantly reduce infections and hospitalizations. The research showed that booster doses are particularly effective in reducing hospitalizations among the elderly and those with comorbidities.
A new study by University of Houston sociologist Kathryn Freeman Anderson reveals significant disparities in the initial COVID-19 vaccine rollout in five urban Texas counties. The research found that Black and Latino neighborhoods were less likely to receive vaccines due to existing healthcare resource shortages.
A global study highlights inadequate information from healthcare professionals and lack of sensitivity leading to child vaccine hesitancy. Expectant parents are seeking alternative sources due to concerns about adverse reactions and long-term side effects, with some fearing measles as a minor childhood illness.
A Kaiser Permanente study found that a third dose of the Pfizer-BioNTech COVID-19 vaccine significantly improved protection against severe disease, hospitalization, and death. The study's results suggest that three doses of the vaccine provide greater benefit than two doses in preventing these outcomes.
A recent study published in Cell found that T cell responses are still robust against the Omicron variant in most individuals with prior SARS-CoV-2 infection or vaccination, offering protection against severe disease. Booster vaccines can enhance T cell responses, substantially increasing immunity against severe COVID-19.
Researchers have confirmed an inhaled vaccine provides long-lasting protection against SARS-CoV-2 and its variants by targeting the lungs and upper airways. The vaccine induces broad respiratory mucosal immunity, outperforming traditional injected vaccines in terms of efficacy and dose requirements.
Researchers attribute vaccine effectiveness to mutations shared with previous variants, resulting in relatively small severe cases and deaths among vaccinated patients. The study analyzed over 200,000 genomes and found identical mutations that could serve as targets for future vaccines.
The IEEE forum identified four major challenges to address during the pandemic: healthcare, screening, tracing, and treatment. The panel highlighted socioeconomic and education status as critical factors impacting mortality rates and hospital admission lengths.
The first US peer-reviewed study on omicron patient outcomes found significant differences in infection behavior. Ominron patients are significantly younger, have increased vaccine breakthrough rates, and are less likely to be hospitalized compared to patients with alpha or delta variants.
A study at a midwestern university examined the relationship between vaccine coverage and the transmission of SARS-CoV-2 variants during in-person learning. The results showed a correlation between higher vaccination rates and reduced spread of variants, highlighting the effectiveness of vaccines in mitigating COVID-19 transmission.
A phase 2 clinical trial found that the Australian-developed neonatal rotavirus vaccine RV3-BB was safe and produced a robust immune response in African babies. The reduced dose of the vaccine generated an equivalent immune response as the highest dose, offering opportunities to reduce vaccine manufacturing costs.
Scientists successfully produced SARS-CoV-2 protein fragments linked to bacterial flagellin in plants, enabling high-yield production and scalable vaccine development. This novel approach could make vaccines cheaper and more convenient.
Researchers at Boston University found no association between COVID-19 vaccination and conception likelihood in female or male partners. However, COVID-19 infection was linked to reduced fertility in men, particularly those testing positive within 60 days of a cycle.
Four COVID-19 vaccines prompt the body to make effective, long-lasting T cells against SARS-CoV-2. These T cells can recognize variants of concern, including Delta and Omicron. Fully vaccinated people have fewer memory B cells and neutralizing antibodies against the Omicron variant.
Researchers at the University of Missouri identified 46 specific mutations in the Omicron variant that enable it to evade pre-existing antibodies. These mutations are particularly prevalent in the region where antibodies bind to the virus, making them a key target for future antiviral treatments.
Researchers are working tirelessly to develop vaccines against the Omicron variant, a crucial step in combating the pandemic. By understanding the biology of Omicron, scientists hope to create effective treatments and boosters to protect against future pandemics.
A new study found that Black Americans who were initially hesitant about receiving a COVID-19 vaccine warmed up to the idea as the pandemic wore on and viewed vaccines as necessary for protection. The research highlights the importance of addressing access barriers, not just distrust or skepticism.
A new study published in the Journal of the American Medical Association finds that those who received the Moderna COVID-19 mRNA vaccine have a lower risk of experiencing 'breakthrough' COVID-19 cases compared to recipients of the Pfizer-BioNTech mRNA vaccine. The study also found that Moderna recipients were less likely to be hospital...
A new study by Boston University School of Public Health investigators finds that COVID-19 vaccination in either partner does not impair fertility. In contrast, males who test positive for COVID within 60 days of a cycle have reduced fertility compared to uninfected men.
A new study by Yale researchers found that the Sinovac vaccine, widely used in 48 countries, offers little protection against the Omicron variant. Booster shots are necessary to combat the dominant circulating virus, which has shown to produce no neutralizing antibodies among those who received two doses of the Sinovac vaccine.
A new study has found that children in sub-Saharan Africa who are hospitalized with COVID-19 are dying at a rate far greater than children in the US and Europe. Children under 1 year old had nearly five times the risk of death compared to adolescents aged 15-19 years.
Researchers at Lund University discovered that non-neutralising antibodies can also protect against Covid-19 by facilitating phagocytosis. The findings suggest that broader protection from antibodies may be more effective in combating mutations of the virus.
A new study by the University of North Carolina at Chapel Hill suggests that COVID-19 vaccines maintain protection from severe disease nine months after the first shot. Boosters are crucial for older adults, according to lead author Danyu Lin, PhD.
A new study from USC researchers sheds light on COVID-19 vaccine inequities in California, revealing disparities in vaccination rates among vulnerable populations. The study suggests that targeted community outreach and improved vaccine access can help reduce these disparities.
A unique Irish study found that previous COVID-19 infection and age are associated with lower antibody levels six months after vaccination. The research highlights the importance of boosting vaccinations for vulnerable populations like nursing home residents.
Researchers found that even unrelated vaccines can provide cross-protection against multiple pathogens, reducing caseloads and hospital usage. Vaccinating vulnerable populations with other vaccines during the pandemic can have a substantial impact.
A case series found that a fourth dose of an mRNA-based vaccine increases antispike IgG titers in kidney transplant recipients with weak serologic response after three doses. The researchers noted no safety concerns with the additional dose and suggested its use for such patients.
A University of Massachusetts Amherst study found that vaccinated women transfer SARS-CoV-2 antibodies to their breastfed infants, potentially giving them passive immunity against the coronavirus. The research also showed a correlation between vaccine side effects and antibody levels in infant stool.
A new study found that COVID-19 vaccination during pregnancy elicits high levels of antibodies in both mother and baby, regardless of when it occurs. The research suggests that pregnant women should not delay vaccination until late pregnancy, as it is likely to be beneficial for themselves and their babies.
Researchers developed a fair-diverse allocation optimization framework to optimize the distribution of COVID-19 vaccines, treatments, and testing supplies. The model aims to get limited resources to the most vulnerable subgroups while ensuring fairness and diversity, independent of demographic background.
The study found that two doses of Moderna and Pfizer vaccines produced higher antibody concentrations than a single dose of Johnson & Johnson vaccine, with levels more than 10 times higher for recovered COVID-19 patients. The analysis also showed that the Moderna vaccine had the lowest risk for breakthrough infections.
Researchers found that mRNA vaccines were highly effective (86%) in preventing SARS-CoV-2-related deaths among vaccinated individuals, especially in the elderly population. However, vaccine effectiveness against infection was lower (69%) and decreased with increasing age and comorbidity burden.
Research from Queen Mary University of London and Cardiff University found that certain MS treatments can reduce Covid-19 vaccine effectiveness in people with MS. The largest peer-reviewed study on the topic provides high-quality evidence to inform clinicians' guidance on treatment options.
A new blood test developed at Hebrew University of Jerusalem detects immune and inflammatory activity in tissues by monitoring circulating DNA fragments. This method provides accurate information about immune processes in remote tissues, removing the need for invasive measures.
Researchers have discovered a fundamental role of the TBK1 enzyme in deciding B cell fate, crucial for developing effective vaccines for diseases like COVID-19 and malaria. The study reveals that TBK1 is necessary for germinal center formation and high-quality antibody production.
Researchers from Harvard University and others have found that large-scale COVID-19 vaccination surveys were off by up to 17 percentage points due to systematic biases in the data. The 'Big Data Paradox' highlights how big data sets can minimize one type of error while magnifying another, leading to misleading results.
The COVID-19 pandemic drove significant advancements in pharmaceutical technology, with mRNA-based vaccines proving highly effective. Oral antiviral pills, such as Merck's molnupiravir and Pfizer's PF-0732133, showed promise in reducing hospitalization and death rates among unvaccinated individuals.
A UK trial shows six different COVID-19 boosters are safe and stimulate strong immune responses in people who have previously received a two-dose course of ChAdOx1-nCov19 or BNT162b2, according to the first randomised trial of boosters given after two doses. The study found varying levels of protection against COVID-19 infection and ho...